The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.
The firms will combine Caris' multimodal genomic data with Ontada's community oncology-based real-world data to support cancer drug development.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...
The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.
The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential.
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
The firm will use the funds to establish a commercial lab and continue advancing its AI- and sequencing-based platform for personalizing cancer treatment.
This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.
NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.
The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback